fexofenadine (allegra) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fexofenadine is a second-generation, long lasting H1-receptor antagonist (antihistamine) which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergy. Fexofenadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Fexofenadine does not enter the brain from the blood and, therefore, does not cause drowsiness. Fexofenadine lacks the cardiotoxic potential of terfenadine, since it does not block the potassium channel involved in repolarization of cardiac cells. Fexofenadine is sold under the trade name Allegra among others. ALLEGRA is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older.   NCATS

Chemistry

  • SMILES: CC(C)(C(=O)O)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4
  • InChIKey: RWTNPBWLLIMQHL-UHFFFAOYSA-N
  • Mol. Mass: 501.67
  • ALogP: 5.51
  • ChEMBL Molecules:
    fexofenadine  
    fexofenadine hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1775 - $0.3536

Australia

$0.4339 - $0.9358
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( fexofenadine (allegra), pseudoephedrine (Benylin) - other names: allegra-d 24 hour allergy and congestion, fexofenadine hcl; pseudoephedrine hcl )

Alternative names

4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid | allegra | allegra allergy | allegra-d | allegra hives | alpha-(4-(1-carboxy-1-methylethyl)phenyl)-4-hydroxydiphenylmethyl-1-piperidinebutanol | aventis behring brand of fexofenadine hydrochloride | aventis brand of fexofenadine hydrochloride | aventis pharma brand of fexofenadine hydrochloride | carboxyterfenadine | fexofenadine | fexofenadine hcl | fexofenadine hydrochloride | fexofenadine hydrochloride allergy | fexofenadine hydrochloride hives | hoechst brand of fexofenadine hydrochloride | mdl 16455 | mdl 16.455 | mdl-16455 | mdl 16,455a | mdl-16455a | telfast | telfast 120 | telfast 180 | telfast 30 | terfenadine acid metabolite | terfenadine carboxylate | terfenadine-cooh

Organizations (92)

Research & Development (73)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (40)

Approved Indications (1)


 

Rhinitis, Allergic, Seasonal

Experimental Indications - Clinical Trial Phases 1-4 (40)


 

Administration, Oral (Phase 1)

Arthritis, Rheumatoid (Phase 1/Phase 2)

Asthma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Chronic Urticaria (Phase 2)

Cold Temperature (Phase 3)

Dermatitis, Atopic (Phase 2/Phase 3)

Diabetic Nephropathies (Phase 4)

Drug Interactions (Phase 1)

Eczema (Phase 1)

Edema (Phase 2)

Exanthema (Phase 1)

Gastroesophageal Reflux (Phase 2)

Gout (Phase 4)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 1)

Hypersensitivity (Phase 4)

Hypertension (Phase 1)

Hypertension, Pulmonary (Phase 1)

Inflammation (Phase 1)

Influenza A virus (Phase 3)

Magnetic Resonance Imaging (Phase 1)

Malabsorption Syndromes (Early Phase 1)

Melanoma (Phase 1)

Multiple Sclerosis, Chronic Progressive (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Neoplasm Metastasis (Phase 1)

Nephrolithiasis (Phase 2)

Pain (Phase 1)

Pharmacokinetics (Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Pruritus (Phase 4)

Psoriasis (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Renal Dialysis (Phase 4)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 4)

Rhinitis, Allergic, Seasonal ()

Urticaria (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 78
  • # of Trial Organizations: 73

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue